HONG KONG – Reviews for priority new drugs in Japan in 2017 took the shortest time in five years, amid the drug watchdog's efforts to cut review lag. The review time for priority new drugs in 2017 was 8.9 months, the shortest since 2013, according to a recent report by the Pharmaceuticals and Medical Devices Agency (PMDA).